- Home
- ATCH vs OGEN Comparison
ATCH vs OGEN Comparison
Compare ATCH & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- OGEN
- Stock Information
- Founded
- ATCH 2022
- OGEN 1996
- Country
- ATCH United States
- OGEN United States
- Employees
- ATCH N/A
- OGEN N/A
- Industry
- ATCH
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- OGEN Health Care
- Exchange
- ATCH Nasdaq
- OGEN Nasdaq
- Market Cap
- ATCH 4.4M
- OGEN 4.6M
- IPO Year
- ATCH N/A
- OGEN N/A
- Fundamental
- Price
- ATCH $0.54
- OGEN $0.21
- Analyst Decision
- ATCH
- OGEN
- Analyst Count
- ATCH 0
- OGEN 0
- Target Price
- ATCH N/A
- OGEN N/A
- AVG Volume (30 Days)
- ATCH 2.1M
- OGEN 357.6K
- Earning Date
- ATCH 05-27-2025
- OGEN 05-14-2025
- Dividend Yield
- ATCH N/A
- OGEN N/A
- EPS Growth
- ATCH N/A
- OGEN N/A
- EPS
- ATCH 2.67
- OGEN N/A
- Revenue
- ATCH N/A
- OGEN N/A
- Revenue This Year
- ATCH N/A
- OGEN N/A
- Revenue Next Year
- ATCH N/A
- OGEN N/A
- P/E Ratio
- ATCH $0.21
- OGEN N/A
- Revenue Growth
- ATCH N/A
- OGEN N/A
- 52 Week Low
- ATCH $0.49
- OGEN $0.19
- 52 Week High
- ATCH $99.00
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- ATCH 28.09
- OGEN 29.94
- Support Level
- ATCH $0.87
- OGEN $0.19
- Resistance Level
- ATCH $1.10
- OGEN $0.22
- Average True Range (ATR)
- ATCH 0.10
- OGEN 0.02
- MACD
- ATCH 0.08
- OGEN -0.01
- Stochastic Oscillator
- ATCH 6.92
- OGEN 20.43
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.